Cabometyx (cabozantinib; Exelixis/Ipsen/Takeda) Drug Overview & Product Profiles 2019 - ResearchAndMarkets.com
VEGF production is upregulated in renal cell carcinoma and results in increased tumor vascularization and disease progression.
- VEGF production is upregulated in renal cell carcinoma and results in increased tumor vascularization and disease progression.
- Standard first-line therapies such as Sutent (sunitinib; Pfizer) work by targeting VEGF/VEGFR signaling; however, tumors often develop resistance to these anti-angiogenic treatments.
- Cabometyx's uptake has been strong, and this is set to continue with the drugs inclusion in combination therapies currently in development.
- The Phase III CheckMate 9ER trial (ClinicalTrials.gov identifier: NCT03141177) is investigating the safety and efficacy of both Cabometyx + Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) doublet therapy and Cabometyx + Opdivo + Yervoy (ipilimumab; Bristol-Myers Squibb/Ono Pharmaceutical) triplet therapy.